Study |
TIme |
Treatment |
Outcome (scale) |
N of pts |
Baseline Mean |
End of Study Mean |
Absolute Benefit |
Relative Difference |
Adams 1995 |
14‐26 wk |
E: Hylan G‐F 20 |
Pain on motion (0‐100 mm VAS) |
29 |
61 |
40 |
‐10 (I) |
‐15.9% (I) |
|
|
C: NSAID |
|
33 |
63 |
52 |
|
|
Adams 1995 |
14‐26 wk |
E: Hylan G‐F 20 |
Pain at night (0‐100 mm VAS) |
29 |
35 |
25 |
‐4 (I) |
‐11.7% (I) |
|
|
C: NSAID |
|
33 |
34 |
28 |
|
|
Adams 1995 |
14‐26 wk |
E: Hylan G‐F 20 |
Pain at rest (0‐100 mm VAS) |
29 |
36 |
25 |
‐4 (I) |
‐13.8% (I) |
|
|
C: NSAID |
|
33 |
29 |
22 |
|
|
Adams 1995 |
14‐26 wk |
E: Hylan G‐F 20 |
Pain overall (0‐100 mm VAS) |
29 |
62 |
47 |
‐5 (I) |
‐8.1% (I) |
|
|
C: NSAID |
|
33 |
62 |
52 |
|
|
Dickson 2001 |
5‐13 wk |
E: Hylan G‐F 20 |
WOMAC pain (0‐100 mm VAS) |
53 |
59 |
26 |
‐10 (I) |
‐16.4% (I) |
|
|
C: Diclofenac |
|
55 |
61 |
38 |
|
|
Dickson 2001 |
5‐13 wk |
E: Hylan G‐F 20 |
WOMAC function (0‐100 mm VAS) |
53 |
54 |
38 |
‐2 (I) |
‐3.6% (I) |
|
|
C: Diclofenac |
|
55 |
56 |
42 |
|
|
Dickson 2001 |
5‐13 wk |
E: Hylan G‐F 20 |
Lequesne Index (0‐24) |
53 |
13.9 |
10.9 |
‐1 (I) |
‐7.2% (I) |
|
|
C: Diclofenac |
|
55 |
13.9 |
11.9 |
|
|
Adams 1995 |
5‐13 wk |
E: Hylan G‐F 20 + NSAID |
Pain on motion (0‐100 mm VAS) |
34 |
60 |
34 |
‐7 (I) |
‐11.1% (I) |
|
|
C: NSAID |
|
33 |
63 |
44 |
|
|
Adams 1995 |
5‐13 wk |
E: Hylan GF 20 + NSAID |
Pain at night (0‐100 mm VAS) |
34 |
20 |
10 |
3 (W) |
8.8% (W) |
|
|
C: NSAID |
|
33 |
34 |
21 |
|
|
Adams 1995 |
5‐13 wk |
E: Hylan G‐F 20 + NSAID |
Pain at rest (0‐100 mm VAS) |
34 |
26 |
14 |
‐3 (I) |
‐10.3% (I) |
|
|
C: NSAID |
|
33 |
29 |
20 |
|
|
Adams 1995 |
5‐13 wk |
E: Hylan G‐F 20 + NSAID |
Pain overall (0‐100 mm VAS) |
34 |
57 |
31 |
‐7 (I) |
‐11.3% (I) |
|
|
C: NSAID |
|
33 |
62 |
43 |
|
|
Adams 1995 |
14‐26 wk |
E: Hylan G‐F 20 + NSAID |
Pain on motion (0‐100 mm VAS) |
32 |
60 |
37 |
‐12 (I) |
‐19% (I) |
|
|
C: NSAID |
|
31 |
63 |
52 |
|
|
Adams 1995 |
14‐26 wk |
E: Hylan G‐F 20 + NSAID |
Pain at night (0‐100 mm VAS) |
32 |
20 |
9 |
‐5 (I) |
‐14.7% (I) |
|
|
C: NSAID |
|
31 |
34 |
28 |
|
|
Adams 1995 |
14‐26 wk |
E: Hylan G‐F 20 + NSAID |
Pain at rest (0‐100 mm VAS) |
32 |
26 |
11 |
‐8 (I) |
‐27.6% (I) |
|
|
C: NSAID |
|
31 |
29 |
22 |
|
|
Adams 1995 |
14‐26 wk |
E: Hylan G‐F 20 + NSAID |
Pain overall (0‐100 mm VAS) |
32 |
57 |
37 |
‐10 (I) |
‐16.1% (I) |
|
|
C: NSAID |
|
31 |
62 |
52 |
|
|